Draft remit - To appraise the clinical and cost effectiveness of certolizumab pegol within its marketing authorisation for treating moderate to severe plaque psoriasis.
Status Proposed
Process STA
ID number 1232

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
21 September 2017 - 19 October 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance